Author: Business Wire

Innovus Pharma Announces Official Launch of its Amazon®, Walmart®, eBay® and Wish® On-Line Stores with a Combined 116 Product SKUs

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced the official launch of its Amazon®, Walmart®, eBay® and Wish

Three New Retail Tenants Coming to TRADE Marketplace & Food Hall

IRVINE, Calif.–(BUSINESS WIRE)–Lincoln Property Company is pleased to announce three new retail tenants to TRADE Marketplace & Food Hall—the thriving retail center that recently underwent a $5 million renovation and is best known for its chef-driven market food hall, which opened last year. The 32,600 square foot food and curated services focused retail center continues to introduce best in class retailers with the addition of three new tenants—Harvard Place Dental, Concourse Optometry, a

Global Eyewear Market Industry Analysis & Outlook 2017-2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Eyewear Market: Industry Analysis & Outlook (2017-2021)” report has been added to ResearchAndMarkets.com’s offering. Regionally, Europe is the major shareholder of the global eyewear market, owing to the increased aging population and urbanization. However, in the coming years, the Asia-Pacific eyewear market is likely to experience significant growth with increasing penetration of soft contact lenses and growing demand for colored lenses in major countr

Glaukos Corporation’s iDose™ Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its Travoprost Intraocular Implant with the iDose™ delivery system continued to provide sustained reduction in intraocular pressure (IOP) in a 12-month interim cohort of patients in its U.S. Investigational New Drug (IND) Phas

GenSight Biologics Receives MHRA Approval to Initiate Phase I/II PIONEER Clinical Trial of GS030 Gene Therapy in Retinitis Pigmentosa

PARIS–(BUSINESS WIRE)–GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced UK Medicines and Healthcare Regulatory Agency (MHRA) acceptance of the Company’s Clinical Trial Application (CTA) to initiate the PIONEER Phase I/II study of GS030 in patients with Retinitis Pigmentosa (RP). PIONEE

RightEye to Exhibit at CES 2018

BETHESDA, Md.–(BUSINESS WIRE)–Press Kit Materials are Available at: http://www.tradeshownews.com/events/ces-2018/RightEyeCES2018/ Company:         RightEye Booth/Stand: 43037   CES 2018 Event: Jan 9 – 12, 2018 Las Vegas, NV, US Web: http://www.righteye.com/ Facebook: https://www.facebook.com/RightEyeInsight Twitter: https://twitter.com/righteyeinsight LinkedIn: https://www.linkedin.com/company/righteye/ About RightEye RightEye is a health technology company using eye tracking and gaming to re

Samenvatting: Novaliq: eerste patiënt ingeschreven voor tweedefaseonderzoek SEECASE naar NOV03 voor behandeling van droge ogen

HEIDELBERG, Duitsland–(BUSINESS WIRE)–Novaliq GmbH, een gespecialiseerd farmaceutisch bedrijf met een revolutionair platform voor medicijntoediening dat slecht oplosbare geneesmiddelen verandert in effectieve oogheelkundige therapieën, heeft vandaag bekendgemaakt dat de randomisatie van patiënten voor fase 2 van het onderzoek SEECASE is begonnen. Dit onderzoek spitst zich toe op de behandeling van droge ogen (dry eye disease, DED). DED is een complexe ziekte aan het oogoppervlak waarbij meerd

Resumen: Novaliq anuncia inscripción del primer paciente en su ensayo de fase 2 SEECASE de NOV03 para el tratamiento de la enfermedad del ojo seco

HEIDELBERG, Alemania–(BUSINESS WIRE)–Novaliq GmbH, una empresa de productos farmacéuticos especiales con una plataforma de administración de fármacos totalmente innovadora que transforma los fármacos pocos solubles en terapias efectivas para oftalmología, ha anunciado que ha comenzado la inscripción aleatoria de pacientes para su ensayo clínico de fase 2 SEECASE para el tratamiento de la enfermedad del ojo seco (EOS). El comunicado en el idioma original, es la versión oficial y autorizada del

Samenvatting: Novaliq sticht dochteronderneming in de Verenigde Staten in Cambridge, Massachusetts, voor versterkte aanwezigheid op groeiende Amerikaanse oogheelkundemarkt

HEIDELBERG, Duitsland–(BUSINESS WIRE)–Novaliq GmbH, een gespecialiseerd farmaceutisch bedrijf met een revolutionair platform voor medicijntoediening dat slecht oplosbare geneesmiddelen verandert in effectieve oogheelkundige therapieën, heeft vandaag de oprichting van een nieuwe dochteronderneming bekendgemaakt, Novaliq Inc. Het nieuwe bedrijf vestigt zich in Cambridge in de Amerikaanse staat Massachusetts. Als opkomende pionier in oogheelkunde voert Novaliq momenteel twee vergevorderde onderz